Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10113131 | 0.86 | GAA (0.79) | GAAADORA2BALDH1A1MEN1KMT2A | |
| SCHEMBL10113442 | 0.86 | GUSB (0.62) | GAAADORA2BALDH1A1MEN1KMT2A | |
| SCHEMBL15930836 | 0.85 | GAA (0.77) | GAAADORA2BALDH1A1MEN1KMT2A | |
| SCHEMBL10113337 | 0.85 | GAA (0.77) | GAAADORA2BALDH1A1MEN1KMT2A | |
| SCHEMBL28589779 | 0.84 | HSD17B10 (0.70) | GAAADORA2BALDH1A1MEN1KMT2A | |
| SCHEMBL10113523 | 0.81 | MEN1 (0.72) | ALDH1A1MEN1KMT2AMAPTTSHR | |
| SCHEMBL10113715 | 0.79 | GAA (0.67) | GAAADORA2BALDH1A1MEN1KMT2A | |
| SCHEMBL10113416 | 0.78 | ADORA2B (0.66) | GAAADORA2BMAPTTSHRHSD17B10 | |
| SCHEMBL13420031 | 0.78 | GAA (0.66) | GAAADORA2BALDH1A1MEN1KMT2A | |
| SCHEMBL10113470 | 0.77 | GAA (0.71) | GAAADORA2BALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | GAA 876/4885ADORA2B 493/4885ALDH1A1 540/4885 |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | GAA 2708/4885ADORA2B 65/4885ALDH1A1 313/4885 |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | GAA 876/4885ADORA2B 493/4885ALDH1A1 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.